Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (FY)Jun 30, 2025 | (FY)Jun 30, 2024 | (FY)Jun 30, 2023 | (FY)Jun 30, 2022 | |
|---|---|---|---|---|
| Operating cash flow (direct method) | ||||
| Cash income from operating activities | ||||
| Cash paid | 11.39%-497.42K | 14.54%-561.39K | -151.10%-656.88K | -261.61K |
| Payments to suppliers for goods and services | 11.39%-497.42K | 14.54%-561.39K | -151.10%-656.88K | ---261.61K |
| Direct interest received | -51.40%49.05K | 14.23%100.92K | 803,090.91%88.35K | --11 |
| Operating cash flow | 2.63%-448.37K | 19.01%-460.47K | -117.33%-568.53K | ---261.6K |
| Investing cash flow | ||||
| Cash flow from continuing investing activities | -56.70%-783.27K | 50.93%-499.84K | -3,908.13%-1.02M | -25.41K |
| Capital expenditure reported | -68.99%-743.27K | 49.18%-439.84K | -3,306.09%-865.56K | ---25.41K |
| Net PPE purchase and sale | 33.33%-40K | 60.78%-60K | ---152.99K | ---- |
| Cash from discontinued investing activities | ||||
| Investing cash flow | -56.70%-783.27K | 50.93%-499.84K | -3,908.13%-1.02M | ---25.41K |
| Financing cash flow | ||||
| Cash flow from continuing financing activities | 0 | 0 | -105.40%-265.38K | 4.92M |
| Net common stock issuance | ---- | ---- | -105.40%-265.38K | --4.92M |
| Cash from discontinued financing activities | ||||
| Financing cash flow | --0 | --0 | -105.40%-265.38K | --4.92M |
| Net cash flow | ||||
| Beginning cash position | -34.57%1.82M | -40.01%2.78M | --4.63M | ---- |
| Current changes in cash | -28.25%-1.23M | 48.16%-960.31K | -140.01%-1.85M | --4.63M |
| End cash Position | -67.76%585.96K | -34.57%1.82M | -40.01%2.78M | --4.63M |
| Free cash from | -28.25%-1.23M | 39.49%-960.31K | -452.97%-1.59M | ---287.01K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP |